317 related articles for article (PubMed ID: 15154599)
1. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
[TBL] [Abstract][Full Text] [Related]
2. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
4. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Michiels JJ
Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799
[TBL] [Abstract][Full Text] [Related]
5. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
6. The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Willoughby S; Pearson TC
Blood Rev; 1998 Mar; 12(1):12-22. PubMed ID: 9597194
[TBL] [Abstract][Full Text] [Related]
7. Erythromelalgia and vascular complications in polycythemia vera.
Michiels JJ
Semin Thromb Hemost; 1997; 23(5):441-54. PubMed ID: 9387203
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Passamonti F; Middeldorp S
Cochrane Database Syst Rev; 2013 Apr; (4):CD006503. PubMed ID: 23633335
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
[TBL] [Abstract][Full Text] [Related]
10. Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; van Vliet HH
Blood Cells Mol Dis; 2006; 36(2):199-205. PubMed ID: 16510297
[TBL] [Abstract][Full Text] [Related]
11. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Michiels JJ; van Genderen PJ; Lindemans J; van Vliet HH
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():47-56. PubMed ID: 8951772
[TBL] [Abstract][Full Text] [Related]
12. Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Jul; 5(3):147-51. PubMed ID: 10725999
[TBL] [Abstract][Full Text] [Related]
13. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Elliott MA; Tefferi A
Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
[TBL] [Abstract][Full Text] [Related]
15. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
16. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
[TBL] [Abstract][Full Text] [Related]
17. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
18. The myeloproliferative disorders. An historical appraisal and personal experiences.
Michiels JJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of bleeding and thrombosis in myeloproliferative disorders.
Landolfi R; Marchioli R; Patrono C
Thromb Haemost; 1997 Jul; 78(1):617-21. PubMed ID: 9198226
[TBL] [Abstract][Full Text] [Related]
20. Aspirin Responsive Thrombotic Complications in Thrombocythemia Vera. A Novel Platelet-Mediated Arterial Thrombophilia.
Michiels JJ
Turk J Haematol; 2002 Jun; 19(2):225-33. PubMed ID: 27264763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]